血清胱抑素C与脑梗死后血管性认知障碍关系的研究  

Relation between serum cystatin C and vascular cognitive impairment following ischemic stroke

作　　者：王大力[1] 何晓娟[2] 安雅臣[1] 张江[1] 赵晓晶[1] 常莉莎[1] 彭延波[1] 

机构地区：[1]河北联合大学附属医院神内二科,唐山063000 [2]河北联合大学

出　　处：《中华老年心脑血管病杂志》2013年第7期684-686,共3页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

摘　　要：目的探讨血清胱抑素C(Cys-C)水平与脑梗死后血管性认知障碍(VCI)的关系。方法选择脑梗死后VCI患者(VCI组)84例及脑梗死后认知正常者(对照组)41例;又根据Cys-C水平分为<607.21μg/L患者31例,607.21～651.93μg/L患者32例,651.94～713.29μg/L患者32例,≥713.30μg/L患者30例。用ELISA双抗体夹心法测定血清Cys-C水平,采用logisitic回归分析Cys-C与脑梗死后VCI的关系。结果与对照组比较,VCI组血清Cys-C水平明显升高,差异有统计学意义(P<0.01)。与<607.21μg/L比较,607.21～651.93μg/L、651.94～713.29μg/L、≥713.30μg/L患者VCI的校正后OR值及95%CI分别为3.334(0.999～11.128)、9.125(2.411～34.537)和16.191(3.193～58.114)。结论血清Cys-C水平升高是脑梗死后VCI的危险因素。Objective To study the relation between serum cystatin C （Cys-C） level and vascular cognitive impairment （VCI） following ischemic stroke. Methods Eighty-four VCI patients fol- lowing ischemic stroke served as a VCI group and 41 VCI patients with normal cognitive function following ischemic stroke served as a control group. The patients were further divided into serum Cys-C level 〈607.21μg/L group （n：31）,serum Cys-C level=607.21-651.93 μg/L group （n= 32） ,serum Cys-C level=651.94-713.29 μg/L group （n=32）,and serum Cys-C level ≥713.30 μg/L group （n=30）. Their serum Cys-C levels were measured by sandwich ELISA. Relation be- tween serum Cys-C level and VCI following ischemic stroke was analyzed by logistic regression analysis. Results The serum Cys-C level was significantly higher in VCI group than in control group （P〈0.01）. The OR value and 95%CI were higher in serum Cys-C level=607.21 -651.93 μg/L group,serum Cys-C level= 651.94-713.29 μg/L group and serum Cys-C level ≥713.30 μg/L group [3. 334 （0. 999-11. 128）,9. 125 （2. 411-34. 537） and 16. 191 （3. 193-58. 114）1 than in serum Cys-C 〈607.21μg/L group. Conclusion Elevated serum Cys-C level is a risk factor for VCI following ischemic stroke.

关 键 词：半胱氨酸蛋白酶抑制剂 脑梗死 认知障碍 动脉粥样硬化 危险因素 

分 类 号：R743.3[医药卫生—神经病学与精神病学] R749.1[医药卫生—临床医学]